SV2003000741A - Compuesto lactamico x-13170 - Google Patents

Compuesto lactamico x-13170

Info

Publication number
SV2003000741A
SV2003000741A SV2001000741A SV2001000741A SV2003000741A SV 2003000741 A SV2003000741 A SV 2003000741A SV 2001000741 A SV2001000741 A SV 2001000741A SV 2001000741 A SV2001000741 A SV 2001000741A SV 2003000741 A SV2003000741 A SV 2003000741A
Authority
SV
El Salvador
Prior art keywords
lactamic
compound
procedures
prepare
methyl
Prior art date
Application number
SV2001000741A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2003000741A publication Critical patent/SV2003000741A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
SV2001000741A 2000-11-17 2001-11-16 Compuesto lactamico x-13170 SV2003000741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
SV2003000741A true SV2003000741A (es) 2003-01-13

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000741A SV2003000741A (es) 2000-11-17 2001-11-16 Compuesto lactamico x-13170

Country Status (33)

Country Link
US (1) US20040248878A1 (OSRAM)
EP (1) EP1353910B1 (OSRAM)
JP (1) JP4116431B2 (OSRAM)
KR (1) KR20030045194A (OSRAM)
CN (2) CN100516047C (OSRAM)
AR (1) AR031356A1 (OSRAM)
AT (1) ATE362919T1 (OSRAM)
AU (2) AU2432102A (OSRAM)
BR (1) BR0115424A (OSRAM)
CA (1) CA2425497C (OSRAM)
CY (1) CY1106682T1 (OSRAM)
CZ (1) CZ20031340A3 (OSRAM)
DE (1) DE60128587T2 (OSRAM)
DK (1) DK1353910T3 (OSRAM)
DZ (1) DZ3454A1 (OSRAM)
EA (1) EA006919B1 (OSRAM)
EC (1) ECSP034598A (OSRAM)
ES (1) ES2286162T3 (OSRAM)
HR (1) HRP20030385A2 (OSRAM)
HU (1) HUP0301862A3 (OSRAM)
IL (1) IL155275A0 (OSRAM)
MX (1) MXPA03004250A (OSRAM)
MY (1) MY141607A (OSRAM)
NO (1) NO325217B1 (OSRAM)
PE (1) PE20020798A1 (OSRAM)
PL (1) PL211018B1 (OSRAM)
PT (1) PT1353910E (OSRAM)
SK (1) SK287794B6 (OSRAM)
SV (1) SV2003000741A (OSRAM)
TW (1) TWI235151B (OSRAM)
UA (1) UA77165C2 (OSRAM)
WO (1) WO2002040451A2 (OSRAM)
ZA (1) ZA200303411B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
NZ540148A (en) 2002-12-20 2007-11-30 Glaxo Group Ltd Benzazepine derivatives for the treatment of neurological disorders
PT1599468E (pt) 2003-01-14 2008-01-14 Arena Pharm Inc Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US8114886B2 (en) 2005-04-08 2012-02-14 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
EP1985615A4 (en) * 2006-01-31 2011-12-14 Api Corp PROCESS FOR THE PREPARATION OF BENZAZEPINONE
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
WO2014171434A1 (ja) 2013-04-19 2014-10-23 国立大学法人岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
JP2023520771A (ja) 2020-03-26 2023-05-19 シージェン インコーポレイテッド 多発性骨髄腫を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0951466T3 (da) * 1996-12-23 2009-03-16 Elan Pharm Inc Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser
JP2002518481A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
EP1230220A1 (en) * 1999-11-09 2002-08-14 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
PT1353910E (pt) 2007-08-20
DK1353910T3 (da) 2007-09-10
MXPA03004250A (es) 2003-09-22
AU2002224321B2 (en) 2006-10-19
NO325217B1 (no) 2008-02-25
CN101624372A (zh) 2010-01-13
JP2004521084A (ja) 2004-07-15
SK5432003A3 (en) 2004-09-08
PE20020798A1 (es) 2002-09-06
ZA200303411B (en) 2004-08-02
EA006919B1 (ru) 2006-04-28
TWI235151B (en) 2005-07-01
EP1353910A2 (en) 2003-10-22
HUP0301862A3 (en) 2007-09-28
WO2002040451A2 (en) 2002-05-23
HRP20030385A2 (en) 2003-08-31
IL155275A0 (en) 2003-11-23
US20040248878A1 (en) 2004-12-09
AU2432102A (en) 2002-05-27
DE60128587T2 (de) 2008-01-31
DZ3454A1 (fr) 2002-05-23
CN100516047C (zh) 2009-07-22
ECSP034598A (es) 2003-06-25
UA77165C2 (en) 2006-11-15
BR0115424A (pt) 2003-10-21
NO20032215D0 (no) 2003-05-15
HUP0301862A2 (hu) 2003-09-29
NO20032215L (no) 2003-07-16
KR20030045194A (ko) 2003-06-09
CY1106682T1 (el) 2012-05-23
ATE362919T1 (de) 2007-06-15
JP4116431B2 (ja) 2008-07-09
AR031356A1 (es) 2003-09-17
ES2286162T3 (es) 2007-12-01
CZ20031340A3 (cs) 2004-06-16
CN1575282A (zh) 2005-02-02
CA2425497A1 (en) 2002-05-23
EP1353910B1 (en) 2007-05-23
WO2002040451A3 (en) 2003-08-28
SK287794B6 (sk) 2011-10-04
PL360991A1 (en) 2004-09-20
MY141607A (en) 2010-05-31
PL211018B1 (pl) 2012-03-30
CA2425497C (en) 2010-08-17
EA200300579A1 (ru) 2003-12-25
DE60128587D1 (de) 2007-07-05

Similar Documents

Publication Publication Date Title
SV2003000741A (es) Compuesto lactamico x-13170
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
HN1999000089A (es) Formulaciones de ziprasidona
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
SE0000540D0 (sv) New compounds
BRPI0411528A (pt) uso de isomalte como prebiótico
BR0215405A (pt) Composições e processos de uso de collajolie
DK1252293T3 (da) Kilde til levervæv
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
SE0301653D0 (sv) Novel compounds
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
SE9901077D0 (sv) Novel use
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
CY1105009T1 (el) Συνθεση καχαλαλιδης f
DK1105114T3 (da) Nimesulidholdige topiske farmaceutiske sammensætninger
SE9801494D0 (sv) Novel use
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
GT200000035AA (es) Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035)
UA88867C2 (ru) Композиция, которая содержит модафинил, и ее применение
BRPI0416678A (pt) pirazolpirimidinas
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål